Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetology International
Published in: Diabetology International 4/2016

01-12-2016 | Original Article

Combination of melatonin and certain drugs for treatment of diabetic nephropathy in streptozotocin-induced diabetes in rats

Authors: Tarek K. Motawi, Samia A. Ahmed, Manal A. Hamed, Shohda A. El-Maraghy, Wessam M. Aziz

Published in: Diabetology International | Issue 4/2016

Login to get access

Abstract

Diabetic nephropathy is a major complication of diabetes and a leading cause of end-stage renal failure in many developed countries. The study aimed to evaluate the efficiency of certain drugs and melatonin in the treatment of nephropathy secondary to diabetes. Diabetes was induced in rats by a single intraperitoneal injection of streptozotocin (50 mg/kg body weight). Three days after induction of diabetes (460–500 mg/dl), rats were treated daily for 60 days with Rowatinex, melatonin, Rowatinex + melatonin, Amosar (Losartan Potassium) (LSP) and LSP + melatonin. The evaluations were made by measuring blood urea nitrogen (BUN), serum uric acid, serum creatinine, urine creatinine, creatinine clearance, nitric oxide, malondialdehyde, superoxide dismutase, glutathione, total antioxidant capacity, kidney injury molecule-1, heat shock protein-70, caspase-3, transforming growth factor β1, and DNA degradation by comet assay and total protein contents. The histopathological picture of the kidneys and pancreases was confirmed in our results. Diabetic rats showed drastic changes in all the measured parameters. Treatment with melatonin and the selected drugs revealed amelioration levels with variable degrees. In conclusion, the combination of LSP and melatonin had the most potent effect on treating the deleterious action of diabetes on rat kidney.
Literature
1.
Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 2005;16:S30–3.CrossRefPubMed
2.
Yoh K, Hirayama A, Ishizaki K, et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells. 2008;13:1159–70.PubMed
3.
Lewis EJ, Xu X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diab Care. 2008;31:S202–7.CrossRef
4.
Schaeffer V, Hansen KM, Morris DR, Abrass CK. Reductions in laminin beta2 mRNA translation are responsible for impaired IGFBP-5-mediated mesangial cell migration in the presence of high glucose. Am J Physiol Renal Physiol. 2010;298:F314–22.CrossRefPubMed
5.
Yozai K, Shikata K, Sasaki M, et al. Methotrexate prevents renal injury in experimental diabetic rats via anti-inflammatory actions. J Am Soc Nephrol. 2005;16:3326–38.CrossRefPubMed
6.
Seon YD, Lee TH, Lee MC. Changes of glomerular basement membrane components in Vacor-induced diabetic nephropathy. Korean J Intern Med. 1999;14:77–84.CrossRefPubMedPubMedCentral
7.
Micah L, Thorp DO. Diabetic nephropathy: common questions. Am Fam Physician. 2005;72:96–9.
8.
Paredes SD, Korkmaz A, Manchester LC, Tan DX, Reiter RJ. Phytomelatonin: a review. J Exp Botany. 2009;60:57–69.CrossRef
9.
Boutin JA, Audinot V, Ferry G, Delagrange P. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci. 2005;26:412–9.CrossRefPubMed
10.
Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nut Metab. 2005;2:22.CrossRef
11.
Reiter R, Acuña-Castroviejo D, Tan DX, Burkhardt S. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann NY Acad Sci. 2001;939:200–15.CrossRefPubMed
12.
Sainz RM, Mayo JC, Rodriguez C, Tan DX, Lopez-Burillo S, Reiter RJ. Melatonin and cell death: differential actions on apoptosis in normal and cancer cells. Cell Mol Life Sci. 2003;60:1407–26.CrossRefPubMed
13.
Alvira D, Tajes M, Verdaguer E, et al. Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson’s disease. J Pineal Res. 2006;40:251–8.CrossRefPubMed
14.
FDA Tightens up Dietary Supplement Manufacturing and Labelling. Medical News Today, 2007. Retrieved 2 Sept 2013.
15.
Mundey K, Benloucif S, Harsanyi K, Dubocovich ML, Zee PC. Phase-dependent treatment of delayed sleep phase syndrome with melatonin. Sleep. 2005;28:1271–8.PubMed
16.
Bach T. Preclinical and clinical overview of terpenes in the treatment of urolithiasis. European Urol. 2010;9:801–26.CrossRef
17.
Cipriani P, Mancini C. Microbiological activity of a terpen product used in the treatment of urinary diseases. Gaz Int Mede Chir. 1972;77–82.
18.
Parving H, Lehnert H, Brochner-Mortansen J, Gomis R, Anderson S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Eng J Med. 2001;345:870–8.CrossRef
19.
Punithavathi VR, Anuthama R, Prince SM. Combined treatment with naringin and vitamin C ameliorates streptozotocin-induced diabetes in male Wistar rats. J Appl Toxicol. 2008;28:806–13.CrossRefPubMed
20.
Bhandari U, Kanojia R, Pillai KK. Effect of ethanolic extract of Zingiber officinale on dyslipidaemia in diabetic rats. J Ethnopharmacol. 2005;97:227–30.CrossRefPubMed
21.
Yavuz O, Camb M, Bukanc N, Guvenb A, Siland F. Protective effect of melatonin on β-cell damage in streptozotocin-induced diabetes in rats. Acta Histochem. 2003;105:261–6.CrossRefPubMed
22.
Romics I, Siller G, Kohnen R, Mavrogenis S, Varga J, Holman E. A Special terpene combination (Rowatinex®) improves stone clearance after extracorporeal shockwave lithotripsy in Urolithiasis patients: results of a placebo-controlled randomised controlled trial. Urol Int. 2011;86:102–9.CrossRefPubMed
23.
Murali B, Goyal RK. Effect of chronic treatment with losartan on streptozotocin induced diabetic nephropathy. Clin Exp Hypertens. 2001;23:513–20.CrossRefPubMed
24.
25.
Moron MS, Depierre JW, Mannervik B. Level of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochem Biophys Acta. 1979;582:67–78.CrossRefPubMed
26.
Nishikimi M, Rae NA, Yagi K. The occurrence of superoxide anion in the action of reduced phenazine methosulphate and molecular oxygen. Biochem Biophys Res Commun. 1972;46:849–53.CrossRefPubMed
27.
Moshage H, Kok B, Huzenge JR, Jansen PL. Nitrite and nitrate determination in plasma: a critical evaluation. Clin Chem. 1995;41:892–6.PubMed
28.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.CrossRefPubMed
29.
Karimi MM, Sani MJ, Mahmudabadi AZ, Sani AJ, Khatibi SR. Effect of acute toxicity of cadmium in mice kidney cells. Iran J Toxicol. 2012;6:691–798.
30.
Suzuki H, Suzuki K. Rat hypoplastic kidney (hpk/hpk) induces renal anemia, hyperparathyroidism, and osteodystrophy at the end stage of renal failure. J Vet Med Sci. 1998;60:1051–8.CrossRefPubMed
31.
Atangwho IJ, Ebong PE, Eteng MU, Eyong EV, Obi AU. Effect of Vernomia amygdalina Del leaf on kidney function of diabetic rats. Int J Pharmacol. 2007;3:143–8.CrossRef
32.
Haligur M, Topsakal S, Ozmen O. Early degenerative effects of diabetes mellitus on pancreas, liver, and kidney in rats: an immunohistochemical study. Exp Diabetes Res. 2012;2:1–10.CrossRef
33.
Wilson GL, Leiter EH. Streptozotocin interactions with pancreatic β cells and the induction of insulin-dependent diabetes. Curr Topics Microbiol Immunol. 1990;156:27–54.
34.
Slauson DO, Cooper BJ (eds.). Pathology—the study of disease. In: Mechanisms of disease a textbook of comparative general pathology. Mosby, St. Louis; 2002, p. 1–15.
35.
Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007;49:355–64.CrossRefPubMed
36.
Tang J, Yan H, Zhuang S. Inflammation and oxidative stress in obesity-related glomerulopathy. Int J Nephrol. 2012;2012:e1–11.CrossRef
37.
Pan QR, Ren YL, Zhu JJ, et al. Resveratrol increases nephrin and podocin expression and alleviates renal damage in rats fed a high-fat diet. Nutrients. 2014;6:2619–31.CrossRefPubMedPubMedCentral
38.
Kirkali G, Gezer S, Umur N. Nitric oxide in chronic liver disease. Turk J Med Sci. 2000;30:511–5.
39.
El-Gengaihi SE, Hamed MA, Khalaf-Allah AM, Mohammed MA. Golden berry juice attenuates the severity of hepatorenal injury. J Diet Suppl. 2013;10:357–69.CrossRefPubMed
40.
Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, Poli G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor beta-1- expression in the macrophage lineage. A link between oxidative energy and fibrosclerosis. FASEB J. 1997;11:851–7.PubMed
41.
Pawluczyk IZ, Harris KP. Macrophages promote prosclerotic responses in cultured rat mesangial cells: a mechanism for the initiation of glomerulosclerosis. J Am Soc Nephrol. 1997;8:1525–36.PubMed
42.
Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diabetes Rep. 2010;10:37–42.CrossRef
43.
Carlsson AC, Calamia M, Rise’rus U, et al. Kidney injury molecule (KIM)-1 is associated with insulin resistance: results from two community-based studies of elderly individuals. Diab Resh Clin Pract. 2014;103:516–21.CrossRef
44.
Sarafidis PA, Ruilope LM. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications. Am J Nephrol. 2006;26:232–44.CrossRefPubMed
45.
Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, Vessby B. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated Creactive protein: a potential link to fatty acid-induced insulin resistance. Circulation. 2002;106:1925–9.CrossRefPubMed
46.
Knight SF, Imig JD. Obesity, insulin resistance, and renal function. Microcirculation. 2007;14:349–62.CrossRefPubMed
47.
Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.CrossRefPubMed
48.
Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D. Kidney injury molecule 1 (KIM-1) and neutrophil gelatinase associated lipocalin (NGAL) with kidney function decline in the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis. 2012;60:904–11.CrossRefPubMedPubMedCentral
49.
Vaidya VS, Niewczas MA, Ficociello LH, Johnson AC, Collings FB, Warram JH. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-beta-d-glucosaminidase. Kidney Int. 2011;79:464–70.CrossRefPubMed
50.
Fink AL. Chaperone-mediated protein folding. Physiol Rev. 1999;79:425–49.PubMed
51.
Kim HJ, Hwang NR, Lee KJ. Heat shock response for understanding diseases of protein denaturation. Moll Cell. 2007;23:123–31.
52.
Barutta F, Pinach S, Giunti S, et al. Heat shock protein expression in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;295:F1817–24.CrossRefPubMed
53.
54.
Maedler K, Spinas GA, Lehmann R. Glucose induces beta-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 2011;50:1683–90.CrossRef
55.
Brezniceanu ML, Liu F, Wei CC. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes. 2008;57:451–9.CrossRefPubMed
56.
57.
Frances DE, Ronco MT, Monti JA. Hyperglycemia induces apoptosis in rat liver through the increase of hydroxyl radical: new insights into the insulin effect. J Endocrinol. 2010;205:187–200.CrossRefPubMed
58.
Lannergren J, Westerblod H, Bruton SD. Dynamic vacuolation in skeletal muscle fibers after fatigue. Cell Biol Int. 2002;26:911–20.CrossRefPubMed
59.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50:536–46.
60.
Woods JA, Young AJ, Gilmore IT. Measurement of menadione-mediated DNA damage in human lymphocytes using the Comet assay. Free Radic Res. 1997;26:113–24.CrossRefPubMed
61.
62.
Shaffie NM, Morsy FA, Ali AG, Sharaf HA. Effect of craway, coriander and fennel on the structure of kidney and islets of Langerhans in alloxan-induced diabetic rats: histological and histochemical study. Researcher. 2010;2:27–40.
Metadata
Title
Combination of melatonin and certain drugs for treatment of diabetic nephropathy in streptozotocin-induced diabetes in rats
Authors
Tarek K. Motawi
Samia A. Ahmed
Manal A. Hamed
Shohda A. El-Maraghy
Wessam M. Aziz
Publication date
01-12-2016
Publisher
Springer Japan
Published in
Diabetology International / Issue 4/2016
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-016-0268-9

Other articles of this Issue 4/2016

Diabetology International 4/2016 Go to the issue

Original Article

Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study

Original Article

Clinical backgrounds associated with discrepancy between subjective and objective assessments of medication adherence in Japanese type 2 diabetic patients

Commentary

Bilirubin as an important physiological modulator of oxidative stress and chronic inflammation in metabolic syndrome and diabetes: a new aspect on old molecule

Report of the committee

New glycemic targets for patients with diabetes from the Japan Diabetes Society

Original Article

Influence of different methods for measuring HbA1c on health checkups in a rural town in Hokkaido, Japan

Original Article

Smoking status is associated with mild cognitive impairment assessed with the mini-mental state examination in Japanese diabetic patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits